Mesothelioma Market

Market Overview:

The 7 major mesothelioma markets reached a value of US$ 434.2 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 905.6 Million by 2034, exhibiting a growth rate (CAGR) of 6.91% during 2024-2034.

The mesothelioma market has been comprehensively analyzed in IMARC's new report titled "Mesothelioma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Mesothelioma refers to a type of cancer that affects the thin layer of tissue (mesothelium) covering the internal organs of the body. The symptoms of the ailment can vary depending on the location of the cancer, but the most common form, pleural mesothelioma, typically presents with indications like coughing, chest pain, shortness of breath, etc. Numerous other manifestations may include fatigue, weight loss, difficulty swallowing, etc. In some cases, patients may also experience abdominal pain and swelling. A definitive diagnosis of the disease can be challenging due to its similarity to other conditions, so a comprehensive evaluation by an experienced team is essential for an accurate prognosis. The diagnostic process may include imaging procedures, such as X-rays, CT scans, MRIs, etc., as well as biopsies to examine tissue samples for signs of cancer. Doctors may also perform pulmonary function tests to evaluate lung function and blood tests to look for biomarkers associated with mesothelioma.

The increasing cases of exposure to asbestos fibers, which become lodged in the lining of the lungs, abdomen, or heart, and cause irritation as well as inflammation, are primarily driving the mesothelioma market. Besides this, the widespread adoption of pleurectomy with decortication for relieving symptoms, such as chest pain and difficulty breathing, and improving survival rates in patients is also propelling the market growth. Furthermore, the escalating utilization of chemotherapy in combination with various other treatments, including surgery or radiation therapy, to shrink tumor size and slow the progression of mesothelioma is acting as another significant growth-inducing factor. Additionally, several key players are making extensive investments in R&D activities to introduce targeted therapies that target specific molecules or pathways involved in the formation and spread of cancer cells. This, in turn, is also creating a positive outlook for the market. Moreover, the introduction of high-resolution CT scanning for detecting abnormalities in the lungs or pleura, which may be indicative of the disease, is expected to drive the mesothelioma market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the mesothelioma market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for mesothelioma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the mesothelioma market in any manner.

Recent Developments:

• In June 2024, RS Oncology announced encouraging findings at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting from its Phase 1 research in patients with malignant pleural mesothelioma and malignant pleural effusion or malignant pleural effusion associated with other solid malignancies.
• In March 2024, Ultimovacs ASA stated that the randomized controlled Phase II clinical study NIPU results had been published in the European Journal of Cancer. The study (NCT04300244) investigates the effect of adding Ultimovacs' cancer vaccine UV1 to second-line treatment with ipilimumab and nivolumab for patients with pleural mesothelioma.
• In November 2023, Polaris Group announced that it had started the rolling submission of its biologic license application for ADI-PEG 20 to the United States FDA for the systemic treatment of patients with malignant pleural mesothelioma with non-epithelioid histology, in combination with a platinum agent and pemetrexed. This submission is based on the findings of a successful phase 3 study of ADI-PEG 20 in combination with a platinum agent and pemetrexed, which fulfilled both the primary and secondary objectives for progression-free survival and overall survival.

Key Highlights:

• Mesothelioma statistics suggest that 3,000 new cases are diagnosed in the United States each year. This is approximately one per 100,000 persons.
• The 5-year survival rate for pleural mesothelioma is 12%, while peritoneal mesothelioma is 65%.
• Men over 65 with employment experiences in the military, construction, industry, mechanics, and firefighters are at particularly high risk of developing mesothelioma.
• Asbestos workers with years of exposure are at an 8% to 13% chance of developing mesothelioma.
• Research demonstrates that women have a longer mesothelioma latency period than men.

Drugs:

ALIMTA, in conjunction with cisplatin, is recommended for the initial therapy of patients with malignant pleural mesothelioma who are unresectable or cannot undergo curative surgery. For patients with a Cockcroft-Gault equation creatinine clearance of 45 mL/min or higher, the recommended dose of ALIMTA with cisplatin is 500 mg/m² administered intravenously over 10 minutes on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.

MTG-201 is a novel experimental biologic in Phase 1 clinical studies to treat prostate cancer and mesothelioma. MTG-201 specifically promotes apoptosis in cancer cells immortalized by hypermethylation of the Dickkopf-3 gene and thus lacks REIC protein.  Apoptosis induces cancer-specific activated T-cell lymphocytes, which are effective against subsequent tumors and residual cancer.  MTG-201 is also assessed for efficacy when combined with anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies.

RSO-021 is a naturally occurring, sulfur-rich cyclic oligopeptide of the thiopeptide class that covalently inactivates PRX3, resulting in severe oxidative stress and cell death. The medicine is delivered weekly directly into the pleural space after malignant pleural effusion drainage using an indwelling pleural catheter.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the mesothelioma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the mesothelioma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current mesothelioma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the mesothelioma market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the mesothelioma market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the mesothelioma market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of mesothelioma across the seven major markets?
• What is the number of prevalent cases (2018-2034) of mesothelioma by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of mesothelioma by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with mesothelioma across the seven major markets?
• What is the size of the mesothelioma patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of mesothelioma?
• What will be the growth rate of patients across the seven major markets?
   

Mesothelioma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for mesothelioma drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the mesothelioma market?
• What are the key regulatory events related to the mesothelioma market?
• What is the structure of clinical trial landscape by status related to the mesothelioma market?
• What is the structure of clinical trial landscape by phase related to the mesothelioma market?
• What is the structure of clinical trial landscape by route of administration related to the mesothelioma market?